AU598282B2 - Solutions of oxazaphosphorins having improved stability and process for the preparation thereof - Google Patents
Solutions of oxazaphosphorins having improved stability and process for the preparation thereof Download PDFInfo
- Publication number
- AU598282B2 AU598282B2 AU75549/87A AU7554987A AU598282B2 AU 598282 B2 AU598282 B2 AU 598282B2 AU 75549/87 A AU75549/87 A AU 75549/87A AU 7554987 A AU7554987 A AU 7554987A AU 598282 B2 AU598282 B2 AU 598282B2
- Authority
- AU
- Australia
- Prior art keywords
- oxazaphosphorin
- solution
- solutions
- preparation
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 238000000034 method Methods 0.000 title claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 40
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims abstract description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 16
- 229960004397 cyclophosphamide Drugs 0.000 claims description 14
- 229960001101 ifosfamide Drugs 0.000 claims description 11
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- -1 2-methanesulfonyloxyethyl Chemical group 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000013019 agitation Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 36
- 239000004480 active ingredient Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000000354 decomposition reaction Methods 0.000 description 6
- 230000000474 nursing effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 239000003708 ampul Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- PWOQRKCAHTVFLB-UHFFFAOYSA-N cyclophosphamide hydrate Chemical compound O.ClCCN(CCCl)P1(=O)NCCCO1 PWOQRKCAHTVFLB-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MRIMWDXKBILRPB-UHFFFAOYSA-N O=P1NCCCO1 Chemical compound O=P1NCCCO1 MRIMWDXKBILRPB-UHFFFAOYSA-N 0.000 description 1
- 239000004086 alkylating cytostatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Paper (AREA)
- Carbon And Carbon Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3623369 | 1986-07-11 | ||
| DE3623369 | 1986-07-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7554987A AU7554987A (en) | 1988-01-14 |
| AU598282B2 true AU598282B2 (en) | 1990-06-21 |
Family
ID=6304930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU75549/87A Expired AU598282B2 (en) | 1986-07-11 | 1987-07-10 | Solutions of oxazaphosphorins having improved stability and process for the preparation thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4952575A (enExample) |
| EP (1) | EP0254902B1 (enExample) |
| JP (1) | JPS6323888A (enExample) |
| KR (1) | KR880001282A (enExample) |
| AT (1) | ATE66609T1 (enExample) |
| AU (1) | AU598282B2 (enExample) |
| CA (1) | CA1289886C (enExample) |
| DE (2) | DE3772482D1 (enExample) |
| DK (1) | DK168322B1 (enExample) |
| ES (1) | ES2038623T3 (enExample) |
| FI (1) | FI86690C (enExample) |
| GR (1) | GR3002618T3 (enExample) |
| IE (1) | IE59897B1 (enExample) |
| IL (1) | IL83141A (enExample) |
| PT (1) | PT85293B (enExample) |
| ZA (1) | ZA875059B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051257A (en) * | 1989-05-09 | 1991-09-24 | Pietronigro Dennis D | Antineoplastic solution and method for treating neoplasms |
| RO113611B1 (ro) * | 1990-08-03 | 1998-09-30 | Asta Pharma Ag | Preparate solide de ifosfamida, administrate oral si procedeu de obtinere |
| US5227373A (en) * | 1991-10-23 | 1993-07-13 | Bristol-Myers Squibb Co. | Lyophilized ifosfamide compositions |
| DE59813853D1 (de) * | 1997-10-13 | 2007-02-01 | Stada Arzneimittel Ag | Flüssige darreichungsformen oxazaphosphorinhaltiger pharmazeutischer produkte |
| US7205404B1 (en) * | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| AUPQ849900A0 (en) * | 2000-06-30 | 2000-07-27 | Dbl Australia Pty Ltd. | Injectable composition |
| US6613927B1 (en) | 2002-02-08 | 2003-09-02 | American Pharmaceutical Partners, Inc. | Sterile lyophilized ifosfamide and associated methods |
| CN1694713A (zh) * | 2002-09-05 | 2005-11-09 | 印度血清及疫苗有限公司 | oxazaphosphorine和美司钠的液态稳定组合物 |
| US7199111B2 (en) * | 2002-12-02 | 2007-04-03 | Bharat Serums & Vaccines Ltd. | Aqueous ifosfamide compositions for parenteral administration and a process for their preparations |
| CA2580202A1 (en) * | 2004-09-13 | 2006-03-23 | Bharat Serums & Vaccines Ltd. | Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy |
| US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
| CN106456654A (zh) * | 2014-05-09 | 2017-02-22 | 奥罗医学制药有限公司 | 环磷酰胺液体浓缩制剂 |
| US9994600B2 (en) | 2014-07-02 | 2018-06-12 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
| US10849916B2 (en) | 2014-07-11 | 2020-12-01 | Dr. Reddys Laboratories Limited | Stable liquid formulations of cyclophosphamide and its impurities |
| WO2016005962A2 (en) | 2014-07-11 | 2016-01-14 | Dr. Reddy’S Laboratories Limited | Stable liquid formulations of cyclophosphamide and processes |
| US10993952B2 (en) * | 2015-02-16 | 2021-05-04 | Leiutis Pharmaceuticals Pvt. Ltd. | Stable ready to use cyclophosphamide liquid formulations |
| RU2020126177A (ru) | 2018-01-09 | 2022-02-10 | Лиганд Фармасьютикалз, Инк. | Ацетальные соединения и их терапевтическое применение |
| WO2022038072A1 (en) * | 2020-08-17 | 2022-02-24 | Sandoz Ag | Parenteral pharmaceutical composition comprising cyclophosphamide and a mixture of liquids |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3530147A1 (de) * | 1985-08-23 | 1987-02-26 | Bayer Ag | Verwendung von diazaphosphorinen zur bekaempfung von endoparasiten |
-
1987
- 1987-07-03 EP EP87109559A patent/EP0254902B1/de not_active Expired - Lifetime
- 1987-07-03 AT AT87109559T patent/ATE66609T1/de not_active IP Right Cessation
- 1987-07-03 DE DE8787109559T patent/DE3772482D1/de not_active Expired - Lifetime
- 1987-07-03 ES ES198787109559T patent/ES2038623T3/es not_active Expired - Lifetime
- 1987-07-03 DE DE19873722043 patent/DE3722043A1/de not_active Withdrawn
- 1987-07-07 JP JP62167976A patent/JPS6323888A/ja active Granted
- 1987-07-09 PT PT85293A patent/PT85293B/pt unknown
- 1987-07-09 IL IL83141A patent/IL83141A/xx not_active IP Right Cessation
- 1987-07-10 DK DK359387A patent/DK168322B1/da not_active IP Right Cessation
- 1987-07-10 CA CA000541835A patent/CA1289886C/en not_active Expired - Lifetime
- 1987-07-10 ZA ZA875059A patent/ZA875059B/xx unknown
- 1987-07-10 FI FI873064A patent/FI86690C/fi not_active IP Right Cessation
- 1987-07-10 AU AU75549/87A patent/AU598282B2/en not_active Expired
- 1987-07-10 IE IE186787A patent/IE59897B1/en not_active IP Right Cessation
- 1987-07-11 KR KR1019870007481A patent/KR880001282A/ko not_active Ceased
-
1989
- 1989-02-06 US US07/307,230 patent/US4952575A/en not_active Expired - Lifetime
-
1991
- 1991-08-29 GR GR91401184T patent/GR3002618T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT85293B (pt) | 1990-03-30 |
| EP0254902A3 (en) | 1988-08-03 |
| AU7554987A (en) | 1988-01-14 |
| PT85293A (de) | 1987-08-01 |
| JPS6323888A (ja) | 1988-02-01 |
| GR3002618T3 (en) | 1993-01-25 |
| CA1289886C (en) | 1991-10-01 |
| IL83141A0 (en) | 1987-12-31 |
| FI86690C (fi) | 1992-10-12 |
| DE3772482D1 (de) | 1991-10-02 |
| EP0254902B1 (de) | 1991-08-28 |
| FI873064L (fi) | 1988-01-12 |
| DK359387D0 (da) | 1987-07-10 |
| IL83141A (en) | 1992-11-15 |
| FI86690B (fi) | 1992-06-30 |
| DE3722043A1 (de) | 1988-01-14 |
| FI873064A0 (fi) | 1987-07-10 |
| ES2038623T3 (es) | 1993-08-01 |
| KR880001282A (ko) | 1988-04-22 |
| DK168322B1 (da) | 1994-03-14 |
| IE871867L (en) | 1988-01-11 |
| EP0254902A2 (de) | 1988-02-03 |
| DK359387A (da) | 1988-01-12 |
| IE59897B1 (en) | 1994-04-20 |
| US4952575A (en) | 1990-08-28 |
| ATE66609T1 (de) | 1991-09-15 |
| ZA875059B (en) | 1988-02-24 |
| JPH0543711B2 (enExample) | 1993-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU598282B2 (en) | Solutions of oxazaphosphorins having improved stability and process for the preparation thereof | |
| JP3833248B2 (ja) | 簡単な組成及び高い生物有効性を有する経口投与のためのシクロスポリンの新規処方物及びその製造法 | |
| EP0546018A1 (en) | FLORFENICOL CONTAINING MEDICINAL PRODUCT. | |
| GB2250197A (en) | Pyroxycam solutions of increased stability and without tissue-damaging effect | |
| DE60215129T3 (de) | Esmolol-enthaltende zubereitungen | |
| WO2001034128A2 (en) | Admixture for intravenous administration of linezolid and other antibacterial agents | |
| ES2215856T3 (es) | Solucion de sal monosodica tetrahidrato de n-(o-(p-pivaloiloxibenceno-sulfonilamino)benzoil)glicina y medicamento que contiene esta solucion. | |
| JP2006257020A (ja) | 安定な高濃度エダラボン注射液 | |
| AU2006269628B2 (en) | Pharmaceutical formulations of endo-N-(9- methyl-9-azabicyclo[3 .3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride | |
| WO2005007168A1 (en) | A stable clozapine suspension formulation | |
| US4301175A (en) | E-Type prostaglandin compositions | |
| AT390881B (de) | Verfahren zur herstellung von pharmazeutischen loesungen von oxazaphosphorinen mit verbesserter stabilitaet | |
| HU220867B1 (en) | Pharmaceutical compositions as a solution, containing bis-triazole derivatives and process for producing them | |
| EP0236280B1 (en) | Injectable pharmaceutical formulations of active principles having general anaesthetic activity | |
| HU202744B (en) | Process for producing parenteral analgetic/antipyretic | |
| GB2141027A (en) | Diltiazem hypolipidemic compositions | |
| EP0140492B1 (en) | L-arginine isoxicamate | |
| DE2721034C2 (enExample) | ||
| US3845192A (en) | Use of analgesic compositions | |
| US3366542A (en) | Pharmaceutical preparations containing gamma-amino-beta-(3:4-chlorophenyl)-butyric acd | |
| AT396870B (de) | Verfahren zur herstellung einer galenischen formulierung zur nasalen verabreichung von serotoninantagonisten | |
| HU180740B (en) | Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity | |
| NZ329247A (en) | Anthelmintic compositions containing solubilised benzimidazoles such as oxfendazole and a carrier including a pyrrolidone | |
| JPH0539226A (ja) | サイトメガロウイルス感染症用薬剤 | |
| RU2240797C1 (ru) | Усовершенствованная водорастворимая форма теофиллина |